Patients' satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. Issue 3 (June 2015)

• Record Type: Journal Article
• Authors: Spano, Jean-Philippe; Azria, David; Gonçalves, Anthony
• Is Part Of: Critical reviews in oncology/hematology. Volume 94:Issue 3(2015)
• Page Start: 270
• Page End: 278
• Publication Date: 2015-06
• Subjects: AC adriamycine, cyclophosphamide -- ALTTO adjuvant lapatinib and/or trastuzumab treatment optimization -- APBI accelerated partial breast irradiation -- ASTRO American society for radiation oncology -- BCS breast-conserving surgery -- CI confidence interval -- CMF cyclophosphamide, methotrexate, fluorouracil -- DM1 a microtubule inhibitor, derivative of maytansine -- EBCTCG Early Breast Cancer Trialists' Collaborative Group -- EGFR epidermal growth factor receptor -- ELIOT electron intraoperative radiotherapy -- ER estrogen-receptor -- FAC fluorouracil, doxorubicin, cyclophosphamide -- FEC fluorouracil, epirubicin, cyclophosphamide -- HER2 human epidermal growth factor receptor 2 -- HRQOL health-related quality of life -- IBTR ipsilateral breast tumor recurrences -- IV intravenous -- NEO-ALTTO neoadjuvant lapatinib and/or trastuzumab treatment optimization -- NSABP national surgical adjuvant breast and bowel project -- SC subcutaneous -- START standardization of breast radiotherapy trial -- TAC docetaxel, anthracycline -- TARGIT targeted intraoperative radiotherapy -- TC docetaxel, cyclophosphamide -- T-DM1 trastuzumab emtansine (trastuzumab-DM1) -- WBI whole breast irradiation; Early breast cancer -- Chemotherapy -- HER2-targeted therapy -- Quality of life -- Radiotherapy -- Satisfaction -- Trastuzumab -- TDM-1; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2015.01.007
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Although breast cancer remains a major cause of cancer death, its related death rate has dropped in the last years through early tumor detection and better available treatments. With the development of innovative techniques and new molecules as well as new routes of administration, local treatment and adjuvant therapy of early breast cancer have evolved, from mutilating, time-consuming and/or painful procedures to breast-conservative ones, sparing healthy tissues, reducing the total dose of treatment and the treatment time which in turn reduce the occurrence and severity of toxicity. In parallel with these improvements leading to an increase in survival rate, patients' health-related quality of life has become a major concern. This review aims at describing the evolution of early breast cancer treatment, and its impact on patients' quality of life, convenience, and satisfaction, including a special insight into emerging human epidermal growth factor receptor 2 (HER2)-targeted therapy.